Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Long-Term Debt Repayments (2017 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $24.9 million as the latest value for Q3 2023.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $24.9 million in Q3 2023 year-over-year; TTM through Dec 2024 was $24.9 million, a 0.0% change, with the full-year FY2023 number at $27.5 million, changed N/A from a year prior.
  • Long-Term Debt Repayments was $24.9 million for Q3 2023 at Cartesian Therapeutics, up from $15.1 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $24.9 million in Q3 2023 to a low of $700000.0 in Q3 2019.
  • A 3-year average of $7.8 million and a median of $2.1 million in 2019 define the central range for Long-Term Debt Repayments.
  • Biggest YoY gain for Long-Term Debt Repayments was 2059.0% in 2020; the steepest drop was 2059.0% in 2020.
  • Cartesian Therapeutics' Long-Term Debt Repayments stood at $2.1 million in 2019, then surged by 619.67% to $15.1 million in 2020, then soared by 64.57% to $24.9 million in 2023.
  • Per Business Quant, the three most recent readings for RNAC's Long-Term Debt Repayments are $24.9 million (Q3 2023), $15.1 million (Q3 2020), and $2.1 million (Q2 2020).